As previously reported, our primary criterion for this study was to decrease PSA levels by 50% as the clinical marker for disease progression.19 Without intervention, when PSA levels reach a level that suggest prostate cancer recurrence (nadir +2 ng/mL), one would expect the patient will continue with that trajectory of progression. This evidence concerns the gene KLK3 and prostate cancer.